# Study of NAC of GA Therapy for Patients With BRPC

> **NCT02926183** · PHASE2 · UNKNOWN · sponsor: **Wakayama Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel

## Key facts

- **NCT ID:** NCT02926183
- **Lead sponsor:** Wakayama Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926183, "Study of NAC of GA Therapy for Patients With BRPC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02926183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*